Endocrine Peptide Test Market Growth Outlook Through 2024-2033

Overview and Scope
Endocrine peptide test refers to a diagnostic test used to measure the levels of specific peptides (small proteins) in the blood or urine that are related to the functioning of the endocrine system. The primary aim of the endocrine peptide test is to diagnose and monitor endocrine disorders by measuring specific peptide hormones in the blood.

Sizing and Forecast
The endocrine peptide test market size has grown strongly in recent years. It will grow from $8.34 billion in 2023 to $9.11 billion in 2024 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increasing government spending, rising prevalence of diabetes, decreasing level of immunity in people across the world, high risk of contracting any chronic diseases, and rising government initiatives.

The endocrine peptide test market size is expected to see strong growth in the next few years. It will grow to $13.03 billion in 2028 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to increasing demand for endocrine peptide test, growth in research and development activities, rise in number of lifestyle diseases, increasing geriatric population, and rising prevalence of diabetes amongst the masses. Major trends in the forecast period include advancement in the endocrine testing method, advancements in product technologies, increasing research and development activities to develop novel testing solutions, growing number of product approval, and shift towards preventive healthcare.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

Segmentation & Regional Insights
The endocrine peptide test market covered in this report is segmented –

1) By Test-Type: Dehydroepiandrosterone Sulphate, Progesterone, Luteinizing Hormone, Thyroid Prolactin, Oestradiol, Human Chorionic Gonadotropin, Thyroid-Stimulating Hormone, Other Test-Types
2) By Technology: Mass Spectroscopy, Immunoassay, Chromatography, Nucleic Acid Based, Other Technologies
3) By End-User: Clinics, Healthcare Centers, Hospitals, Commercial Laboratories

North America was the largest region in the endocrine peptide test market in 2023. The regions covered in the endocrine peptide test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16675&type=smp

Major Driver Impacting Market Growth
The rising prevalence of diabetes is expected to propel the growth of the endocrine peptide test market going forward. Diabetes refers to a group of diseases that result in high blood sugar (glucose) levels. The prevalence of diabetes is increasing due to factors such as unhealthy diets, sedentary lifestyles, genetic predisposition, and an aging population. Endocrine peptide test, including hemoglobin A1c, fasting plasma glucose, and C-peptide tests, is used in diabetes to diagnose the condition, monitor glucose levels, and assess insulin production and sensitivity. For instance, in 2021, according to the International Diabetes Federation, a US-based umbrella organization of over 230 national diabetes associations in 170 countries, approximately 537 million adults (20-79 years) were living with diabetes in the world. The total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the rising prevalence of diabetes is driving the endocrine peptide test market.

Key Industry Players
Major companies operating in the endocrine peptide test market are Siemens AG, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Sciex, Bio-Techne Corporation, Invitae Corporation, ARUP Laboratories, Genova Diagnostics, Boston Heart Diagnostics Corporation, Immunodiagnostic Systems Ltd., Mayo Clinic Laboratories

The endocrine peptide test market report table of contents includes:

1. Executive Summary
2. Endocrine Peptide Test Market Characteristics
3. Endocrine Peptide Test Market Trends And Strategies
4. Endocrine Peptide Test Market – Macro Economic Scenario
5. Global Endocrine Peptide Test Market Size and Growth
.
.
.
32. Global Endocrine Peptide Test Market Competitive Benchmarking
33. Global Endocrine Peptide Test Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Endocrine Peptide Test Market
35. Endocrine Peptide Test Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model